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Abstract 
Many hemostatic factors are associated with age and age-related diseases, however 
much remains unknown about the biological mechanisms linking aging and hemostatic 
factors. DNA methylation is a novel means by which to assess epigenetic aging, which is a 
measure of age and the aging processes as determined by altered epigenetic states.  
We used a meta-analysis approach to examine the association between measures of 
epigenetic aging and hemostatic factors, as well as a clotting time measure. For fibrinogen, we 
used European and African-ancestry participants who were meta-analyzed separately and 
combined via a random effects meta-analysis. All other measures only included participants 
of European-ancestry. We found that 1-year higher extrinsic epigenetic age as compared to 
chronological age was associated with higher fibrinogen (0.004 g/L per year; 95% CI: 0.001, 
0.007; P = 0.01) and plasminogen activator inhibitor 1 (PAI-1; 0.13 U/mL per year; 95% CI: 
0.07, 0.20; P = 6.6x10-5) concentrations as well as lower activated partial thromboplastin time, 
a measure of clotting time. We replicated PAI-1 associations using an independent cohort. To 
further elucidate potential functional mechanisms we associated epigenetic aging with 
expression levels of the PAI-1 protein encoding gene (SERPINE1) and the three fibrinogen 
subunit-encoding genes (FGA, FGG, and FGB), in both peripheral blood and aorta intima-
media samples. We observed associations between accelerated epigenetic aging and 
transcription of FGG in both tissues. Collectively, our results indicate that accelerated 
epigenetic aging is associated with a pro-coagulation hemostatic profile, and that epigenetic 
aging may regulate hemostasis in part via gene transcription. 
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Introduction 
Hemostatic factors are circulating proteins that are critical factors in, or indicators of 
the blood clotting/coagulation process. They include, but are not limited to, fibrinogen, factor 
VII (FVII), factor VIII (FVIII), von Willebrand factor (vWF), plasminogen activator-inhibitor 
1 (PAI-1), and D-dimer. Dysregulation and/or deficiency of hemostatic factors can cause 
bleeding events and thrombotic disorders,1-5 and elevated levels of some hemostatic factors 
are associated with cardiovascular outcomes such as coronary heart disease 6,7, incident and 
recurrent myocardial infarction 8-10, peripheral arterial disease,9,11,12 and venous 
thrombosis.13,14  
Advancing age is often associated with an altered hemostatic factor profile typified by 
heightened plasma concentrations of hemostatic factors such as fibrinogen and coagulation 
factor VII (FVII).15-17 This age-associated “prothrombotic” hemostatic profile may contribute 
to associations between age and cardiovascular disease.18,19 Typically, studies of aging are 
performed by comparing the hemostatic/clinical profiles of patients with their chronological 
age. Though effective, this approach does not inform on the underlying biological changes 
linking aging and altered hemostatic profiles.  
Biomarkers of molecular aging have been developed in recent years using  
epigenetic20,21 and transcriptomic22 data. In the case of epigenetics, these biomarkers appear to 
be weakly correlated with telomere length,23-25 a traditional molecular biomarker of aging, 
and independently associated with both age and mortality.24 Epigenetic age acceleration 
effects are often tissue specific20,26 and associated with a number of clinical outcomes 
including: mortality,24,27 obesity,26 cancer,28,29 cardiovascular disease,29 HIV-1 infection,30 and 
traumatic stress.31 However, the association between epigenetic aging biomarkers and 
hemostatic factors has yet to be investigated.  
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Here, we present the first study into the relationship between epigenetic aging 
biomarkers and hemostatic factors. Accelerated epigenetic aging may underlie the association 
between alterations in the hemostatic profile and aging, and reveal novel mechanisms of 
hemostatic regulation.   
Methods: 
Participating Cohorts: 
A total of 11 studies from the Cohorts for Heart & Aging Research in Genomic 
Epidemiology (CHARGE) Hemostasis Working Group participated in these analyses 
(Supplemental Table 1).32 The Framingham Heart Study (FHS) and Cardiovascular Health 
Study (CHS) contributed multiple sets of data which were analyzed separately. Datasets from 
CHS were non-overlapping in participants, whereas data from FHS was longitudinal and 
collected over the course of 3 consecutive examinations of the Offspring cohort (1991-1995, 
1995-1998, & 1998-2001). Plasma levels of five hemostatic factors and one measure of 
clotting time were examined (units used for analysis given in parentheses): fibrinogen (g/L), 
PAI-1 (U/mL), D-dimer (ng/mL), FVII (%), vWF (%), and activated partial thromboplastin 
time (aPTT; s); selected based on their availability in at least three independent cohorts. 
Fibrinogen and PAI-1 were also assessed in an independent sample of 1,427 individuals from 
the FHS Generation 3 (FHS Gen3) cohort, which were held out of discovery analyses to be 
used for replication. These samples were treated and analyzed in an identical manner as the 
discovery FHS samples. A complete description of each study and the methods used to 
measure each hemostatic factor are given in the Supplemental Materials. 
Epigenetic Aging Assessment: 
All cohorts assessed DNA methylation via the Illumina Infinium 
HumanMethylation450 array using methods described in the Supplemental Materials. In order 
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to assess epigenetic aging, an online calculator was used, https://dnamage.genetics.ucla.edu/, 
which takes as input methylation beta values, chronological age, sex, and tissue type and 
estimates multiple epigenetic aging measures.20 We primarily used two epigenetic measures 
for this analysis, both of which assess deviations of epigenetic age from chronological age: 
Extrinsic Epigenetic Age Acceleration Difference (EEAD) and Intrinsic Epigenetic Age 
Acceleration Difference (IEAD). IEAD is a blood-specific measure of aging which adjusts the 
“standard” tissue agnostic measure20 for the following blood immune cell counts imputed 
from methylation data: naïve CD8+ T cells, exhausted CD8+ T cells, plasma B cells, CD4+ T 
cells, natural killer cells, monocytes, and granulocytes.33 EEAD is calculated by weighting the 
global epigenetic age measure by imputed blood immune cell counts, and is thus designed to 
track aging of the immune system as assessed by DNA methylation changes. The term 
“difference” in IEAD and EEAD refers to taking the difference between the epigenetic aging 
measures and chronological age. Differences between epigenetic and chronological age are 
associated with outcomes such as mortality,34 and may indicated accelerated aging. Cell 
counts for IEAD and EEAD were estimated based on methylation data following the 
Houseman35 and Horvath36 methods.  
As EEAD and IEAD are blood-specific measures, we used age acceleration difference 
(AAD) to assess differences between epigenetic and chronological age in non-blood tissues, 
i.e. aorta intima-media. AAD is calculated as the difference between the original, tissue
agnostic DNA methylation age measure20 and chronological age. AAD and IEAD are 
correlated in blood.27 For AAD, EEAD, and IEAD the cohorts performed a common filtering 
approach used in previous meta-analyses of epigenetic aging measures.27 This approach 
removed individuals whose sex from their epigenetic profile differed from their reported sex 
and samples where the estimated cell type was not peripheral blood, and samples whose 
correlation with internal standards used by the online calculator was < 0.80.  
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Statistical Analyses: 
We used two models to understand the relationship between our measures of 
epigenetic aging and hemostatic factors. For each model the hemostatic factor was the 
outcome while the epigenetic aging measure was the predictor. The first model was a basic 
model which adjusted for chronological age, (chronological age)2, and sex. The second (full) 
model adjusted for the basic model terms plus body mass index (BMI, kg/m2), physical 
activity (active vs inactive), and smoking status (current, former, never). The terms in the full 
model were chosen to provide an adjustment for potential confounders from lifestyle without 
including alternative cardiovascular outcomes of interest, such as blood pressure or history of 
cardiovascular disease, as including these colliders could introduce bias.37 For studies that did 
not have a specific variable (e.g. physical activity), it was left out of the model. The basic 
model was our primary model and all cohorts had the complete covariate information 
necessary for this model. 
In FHS, CHS, and ARIC the epigenetic age measures were based on methylation 
assessed at a different examination than the hemostatic factor measurement thus an age 
difference term was calculated as the difference between the chronological age at methylation 
assessment and chronological age when the hemostatic factors were assessed. Linear and 
quadratic age difference terms were added to the models. We evaluated the effect of this 
approach on the observed associations by comparing the association between epigenetic age 
at a single time point and the same hemostatic factor assessed over multiple time points in 
FHS. Since FHS had hemostatic measures taken at multiple time points but DNA methylation 
data only at a single time point (FHS exam 8), we used the assessment closest to the 
methylation assessment. For CHS and ARIC there was a single assessment of DNA 
methylation and a single assessment of the hemostatic factors available, each done at a 
different time point. For cohorts with family data only independent probands were used. The 
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exception to this is the French-Canadian Family study on Factor V Leiden Thrombophilia 
(F5L) which is a study sample composed of 5 large multigenerational families. For this cohort 
family structure was adjusted for in the models via a variance components models 
implemented in the pedigreemm package in R.38   
We used the metafor package39 in R40 to perform meta-analyses. We required that 
hemostatic factors have at least 3 cohorts reporting for the meta-analysis. For all outcomes 
except PAI-1 we had both European and African ancestry cohorts (Supplemental Table 1), 
however fibrinogen was the only outcome with at least 3 cohorts reporting for both 
ethnicities, thus fibrinogen was the only hemostatic factor for which we performed race-
specific meta-analyses. Initial analyses suggested there was some heterogeneity in the 
European ancestry fibrinogen estimates (Cochran’s Q P-value < 0.05), thus for fibrinogen we 
used a random-effects meta-analysis for the European-ancestry and combined ethnicity meta-
analyses. For all other analyses a fixed-effects meta-analysis was used as little evidence of 
heterogeneity was observed. To facilitate comparison with the fixed effects models for other 
outcomes, we also performed a fixed effects meta-analysis for fibrinogen as a sensitivity 
analysis. We considered associations statistically significant after a Bonferroni correction but 
also report associations that achieved a nominal statistical significance level of P < 0.05 as 
these may also be of interest. Previous analyses have observed sex-specific associations with 
epigenetic aging.27 We used a multiplicative interaction model to determine if there was an 
interaction between sex and epigenetic aging measures. 
Associations with peripheral blood gene expression 
To better understand the role of transcriptional regulation in our associations, we used 
data from the Cooperative Health Research in the Region of Augsburg S4 examination 
(KORA S4) and the Rotterdam Study (RS) to examine the association between our epigenetic 
aging measures and the peripheral blood expression of genes for the significant hemostatic 
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factors. For KORA41 and RS gene expression was assessed on the Illumina HumanHT-12v3 
and Illumina HT-12v4 Expression BeadChip arrays, respectively. Both studies isolated RNA 
from whole blood using PAXGene Blood RNA kits (Qiagen; Hilden, Germany). For both 
cohorts, samples with a RNA quality score < 7 were excluded from amplification and 
analysis, and the final gene expression values were log2-transformed. A total of 731 gene 
expression samples passed quality control and had epigenetic aging assessed in RS, while 439 
samples were included in the analysis for KORA S4. Full details are available in the 
Supplemental Materials. In addition to the cross-sectional gene expression analyses done 
using gene expression from KORA S4 and RS, we performed a prospective gene expression 
analysis using KORA F4, since prospective analyses are less influenced by reverse 
confounding. In this analysis we examined the association between epigenetic aging measures 
assessed in KORA S4 samples and gene expression from the same individuals measured 
during the follow-up KORA F4 study. 
We used the same variables for confounder adjustment, in basic and full models, as 
previously described for all gene expression analyses, and additionally included terms for 
RNA integrity number and amplification plate. The log2-transformed gene expression was the 
outcome in all models. For the cross-sectional analyses in KORA S4 and RS we examined the 
results from a fixed-effects meta-analysis. Given the limited number of genes assessed and the 
high correlation between probes for the same gene, associations were considered significant at 
the P < 0.05 level. We refer to the gene expression results according to the study in which the 
gene expression was assessed, thus KORA F4 gene expression results refer exclusively to the 
prospective gene expression analyses, while KORA S4 gene expression results refer 
exclusively to the cross-sectional analyses using KORA S4 gene expression and epigenetic 
aging measures. 
Aortic intima-media expression 
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We also examined the association between epigenetic aging and gene expression in 
aortic intima-media samples to 1) validate peripheral blood associations and 2) evaluate 
tissue-specific associations. We used samples from 22 patients with overlapping methylation 
and gene expression from the Advanced Study of Aortic Pathology biobank (ASAP). 
Methylation was assessed on the Illumina Infinium HumanMethylation450 array, and gene 
expression was assayed using the Affymetrix GeneChip® Human Exon 1.0 ST array from 
RNA isolated using the RNeasy Mini Kit (QIAGEN).42 Full details for ASAP are available in 
the Supplemental Materials. The same adjustment models as before were used with the 
exception that amplification plate and RNA Integrity Number were not included, smoking 
was assessed as current, former, or never, and physical activity was assessed as the number of 
days exercised per week. Smoking and physical activity were included as linear variables. 
Clinical covariates for all gene expression analyses are given in Supplemental Table 2. 
Results 
Baseline characteristics of all studies are given in Supplementary Table 1. For the 
discovery analyses, each of the 5 hemostatic factors examined we had between 3 and 11 
cohorts participating in the meta-analyses. PAI-1 was the only hemostatic factor not measured 
in any of the African-ancestry studies. Distributions of the hemostatic factors were 
comparable across the ancestries except for the African Americans in ARIC who had higher 
D-dimer values and lower FVII values. The age range of participating studies was from 36.9 y 
to 79.1 y and studies varied from 28.6 to 60.7 in percentage of male participants. The sample 
size for each of the assessed outcomes ranged from 3,875 (aPTT) to 16,545 (fibrinogen). For 
the replication in the 3rd Generation Framingham Heart Study (FHS Gen3) the mean age was 
45.5 y and 48.6% of the cohort were males. The two hemostatic factors assessed in FHS Gen3 
were fibrinogen (n = 1,388) and PAI-1 (n = 1,402). In using FHS to evaluate the assessment 
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of epigenetic age at different time points from the hemostatic factor, exam closest in time to 
the hemostatic measurement had the strongest (by magnitude of the effect estimate) 
association, but the confidence intervals for all estimates largely overlapped (Supplemental 
Figure 1). 
Associations between epigenetic aging and hemostasis measures 
We examined six outcomes and two measures of epigenetic aging in the analyses, 
thus, the Bonferroni cutoff was set at P < 0.0042 (0.05/12). Results for all outcomes are given 
in Supplemental Tables 3 and 4, which also contain summary statistics of regressions of the 
hemostatic factors on AAD for reference purposes. The basic model was considered the 
primary model on which we based determinations of statistical significance. 
PAI-1 was significantly associated with both epigenetic age acceleration measures in 
both the basic and full models (Table 1, Figure 1). Fibrinogen was the most widely available 
hemostatic factor with both European (8 cohorts, n = 13,183) and African-ancestry (3 cohorts, 
n = 3,362) cohorts represented. We observed significant associations between both measures 
of blood DNA methylation age and fibrinogen in the African-ancestry cohorts (Supplemental 
Tables 3, 4). In the combined-ethnicity analyses we observed a significant association for 
EEAD and fibrinogen in the basic model which was attenuated slightly in the full model. 
(Figure 2, Table 1). To facilitate comparison with fixed-effects models used for the other 
hemostatic factors we also performed fixed-effects meta-analysis for fibrinogen for both 
EEAD and IEAD (Supplemental Table 5). Results mirrored the random effects meta 
analyses with slightly smaller standard errors and evidence of heterogeneity in some models. 
The clotting time measure aPTT was significantly associated with EEAD in the basic model. 
This association was somewhat attenuated in the full model (Table 1).  
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A summary of all associations is given in Table 2. Overall, accelerated epigenetic 
aging was associated with higher clotting factor concentration (fibrinogen and PAI-1) and 
decreased clotting time (aPTT). For fibrinogen and aPTT, associations were attenuated in the 
confounder-adjusted full model. As a sensitivity analysis, we removed all cohorts with 
hemostatic measures and DNA methylation arrays not performed on the same sample. This 
restriction removed all the African-American ancestry cohorts and left 7 European-ancestry 
cohorts with fibrinogen measured (N = 6,461) and three European-ancestry cohorts with PAI-
1 measured (N = 767). The results were basically unchanged in this sensitivity analysis 
(Supplemental Figures 2 and 3). Despite ARIC having higher values of D-dimer and lower 
values of FVII than the other cohorts, little to no heterogeneity was seen in the meta-analyses 
of these outcomes (Supplemental Tables 3 and 4). Though all epigenetic aging measures 
were strongly associated with sex (Supplemental Table 6), there were no significant sex-
interactions in the meta-analysis after a multiple test correction (Supplemental Table 7).  
Replication in FHS Gen3 
We used an independent cohort of individuals from FHS Gen3 to attempt to replicate 
associations with PAI-1 and fibrinogen. We successfully replicated the PAI-1 associations 
with IEAD and EEAD, but fibrinogen was not associated with epigenetic aging in FHS Gen3 
(Table 3). 
Gene expression analyses 
Given the observed associations with fibrinogen and PAI-1, we examined associations 
between epigenetic aging measures and whole blood gene expression for the three genes 
(FGA, FGB, FGG) which encode the fibrinogen subunits, as well as SERPINE1, which 
encodes PAI-1. In a meta-analysis of cross-sectional associations from KORA S4 and RS, we 
observed associations for FGA and SERPINE1.  EEAD was associated with FGA gene 
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expression for both the basic and full models while SERPINE1 was negatively associated with 
IEAD in the basic model (Table 4a).  
Given the potential for reverse causation when examining epigenetics and gene 
expression, we examined, in a prospective model, the association between epigenetic aging 
assessed in KORA S4 with gene expression measured in KORA F4, a follow-up survey of 
KORA S4 participants. We did not observe associations with FGA or SERPINE1 in the 
prospective model but did observe an association between IEAD and FGG (Table 4b). 
To understand the tissue specificity of the associations, we examined associations 
between gene expression and epigenetic aging in aortic intima-media, a second tissue type we 
had access to that had the necessary DNA methylation and hemostatic factor measurements. 
All of the genes considered are primarily expressed in tissues other than whole blood as 
indicated by data from the human genotype tissue expression consortium,43,44 Supplemental 
Figure 4.  We only examined AAD in these tissue samples since EEAD and IEAD are blood-
specific measures due to their dependence on blood immune cell counts. We observed an 
association between AAD and both FGG and FGB gene expression, though the association 
with FGB was negative. The FGG association was similar to prospective KORA F4 
associations with IEAD (Table 4b).  
Discussion 
Hemostatic factors, such as fibrinogen and PAI-1, are risk factors for multiple adverse 
cardiovascular outcomes.7,9,10,14 As hemostatic factors measures are associated with age, it is 
possible that age-related biological mechanisms influence the regulation and thus 
concentration of hemostatic factors. Here, our results show that higher epigenetic age as 
compared with chronological age is associated with higher concentrations of fibrinogen and 
PAI-1 and decreased clotting time. These associations mirror the alterations in the hemostatic 
profile seen with advancing age. Although coagulation and thrombosis is a balance between 
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pro- and anti-coagulation, as well as pro- and anti-thrombolysis, higher fibrinogen and PAI-1, 
along with lower clotting time, may indicate a shift towards a “prothrombotic” hemostatic 
profile. 
PAI-1 
PAI-1 is a serine protease inhibitor which slows the cleavage of plasminogen to 
plasmin by inhibiting urokinase plasminogen activator. PAI-1 is a risk factor for 
cardiovascular disease and thrombosis45. In mice PAI-1 deficiencies are protective against 
liver fibrosis and carotid artery atherosclerosis progression.46,47 However, in humans, 
individuals homozygous for a PAI-1 frame-shift mutation experienced abnormal bleeding but 
no other abnormalities. Heterozygous individuals did not experience abnormal bleeding 
events.48. Like other hemostatic factors, PAI-1 is strongly associated with age, and may partly 
underlie associations between advanced age and cardiovascular outcomes18. All epigenetic 
biomarkers of accelerated aging we examined were associated with higher PAI-1 
concentrations. We did not find evidence that the epigenetic regulation of PAI-1 is influenced 
by the regulation of mRNA levels of SERPINE1, its coding gene, as none of the accelerated 
epigenetic aging measures were associated with SERPINE1 gene expression in peripheral 
blood or in aortic intima-media. However, this may be due to SERPINE1 being only 
moderately expressed in blood as compared to other tissues such as endothelial cells, and 
arteries, and thus blood transcriptomic levels may not properly reflect PAI-1 regulation. 
Fibrinogen 
Fibrinogen is an essential hemostatic factor and primary phase inflammation marker. 
As such, fibrinogen dysregulation plays a causal role in multiple bleeding disorders49,  is a 
risk factor for cardiovascular disease,6,7 and is associated with mortality.7,50 Fibrinogen was 
associated with multiple measures of accelerated epigenetic aging, most strongly and 
consistently with EEAD, which strongly correlates with epigenetic aging of the immune 
 
17 
system. We also found evidence that accelerated epigenetic aging was associated with 
transcription of the fibrinogen gene cluster (FGA, FGB, FGG). As with PAI-1, the 
associations observed here would be proxies as fibrinogen is primarily expressed in the liver 
(Supplemental Figure 4). In a study of liver biopsy samples from German individuals with 
non-alcoholic fatty liver disease and controls (biopsy samples from exclusion of liver 
malignancy) there was no association between FGA, FGB, or FGG gene expression and 
Horvath epigenetic age acceleration.26 However, this should still be examined in a population 
free of disease as non-alcoholic fatty liver disease is known to affect hemostasis.51,52 In a 
prospective analysis, higher baseline IEAD was associated with higher levels of FGG 
transcription at follow-up. This association mirrored cross-sectional associations in aortic 
tissue where higher AAD, a tissue agnostic epigenetic aging measure correlated with IEAD, 
was also associated with higher FGG transcription. Given that mortality and other health 
outcomes have associations with both accelerated epigenetic aging and fibrinogen, future 
studies should evaluate if associations between epigenetic aging and health outcomes are 
partially mediated by fibrinogen. 
Strengths and Limitations 
A strength of these analyses is the large sample size of the discovery datasets. For the 
analysis of fibrinogen, 11 cohorts participated, which included both European and African-
ancestry individuals. For the other outcomes we were limited to European-ancestry 
individuals. Future meta-analyses should include cohorts representing a diverse array of 
ethnicities, particularly underrepresented ancestry groups. Another limitation is the cross-
sectional design, which is not robust to reverse confounding like a prospective design would 
be. However, we demonstrated associations between epigenetic aging and the transcription of 
FGG using a prospective design that is robust to reverse confounding, suggesting that our 
observations are not entirely driven by bias introduced from reverse confounding effects. 
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Estimates of the association between epigenetic aging and the hemostatic factors were in 
many cases modest. This is to be expected given other modest associations between DNA 
methylation age and outcomes such as mortality,27 though it does not eliminate the possibility 
of substantial increased population health burden from modest individual effects, or large 
individual effects for persons with severe epigenetic aging. 
Another strength of this study was our ability to evaluate associations between 
accelerated epigenetic aging and gene expression in multiple human tissues. This yielded 
important clues into the links between accelerated epigenetic aging and transcriptomic 
regulation of the genes for PAI-1 and fibrinogen. Notably, we were also able to use 
prospective analyses, which are robust to reverse confounding, to show that associations in 
blood are similar to those observed in aortic intima-media tissue. We were limited in our 
analysis of epigenetic aging in aorta intima-media tissue as we had only a few samples (N = 
22). Expanding both the number of samples and the diversity of tissues should be a key focus 
for future studies, particularly given the tissue-specific nature of both DNA methylation and 
gene expression. These studies should particularly collect tissue samples where the hemostatic 
measures are primarily expressed, such as liver for fibrinogen. 
Conclusion 
In conclusion, we observed multiple associations between epigenetic markers of accelerated 
aging and hemostatic factors, which together suggest that accelerated epigenetic aging is 
associated with a prothrombotic hemostatic profile. Advanced age has long been associated 
with a prothrombotic state, which may underlie associations between age and clinical 
outcomes, and these analyses suggest that DNA methylation may play an important role in 
understanding associations between aging, hemodynamics, and clinical outcomes. In the case 
of fibrinogen, we found evidence that accelerated aging drives gene transcription in multiple 
tissue types. Given these observations, as the overlap between the outcomes associated with 
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hemostatic factors and those associated with epigenetic aging increase, researchers should 
evaluate if altered hemostatic regulation is a means by which epigenetic aging associates with 
adverse health outcomes. 
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Table 1. Meta-analysis associations between accelerated epigenetic aging and hemostatic factors.  
Basic and full model associations for hemostatic factor – epigenetic aging associations which were Bonferroni significant, P < 4.16x10-3, in the 
basic model associations. Effect estimates (Beta) are given per one year higher epigenetic age as compared to chronological age. Basic model 
adjusted for age, age2, and sex. Full model adjusted for age, age2, sex, body mass index, physical activity, and smoking. For fibrinogen estimates are 
given for the random effects meta-analysis. aPTT = accelerated partial thromboplastin time; Beta = effect estimate; CI = 95% confidence interval; 
EA = European ancestry population; EEAD = extrinsic epigenetic age acceleration difference; IEAD = intrinsic epigenetic age acceleration 
difference; PAI-1 = plasminogen activator inhibitor-1; P(Q) = heterogeneity (Cochran’s Q) P-value; SE = standard error * = combined-race meta-
analysis  
Table 1. Significant associations 
Basic Full 
Outcome Aging Measure (y) Beta SE CI P P(Q) Beta SE CI P P(Q) 
PAI-1 (U/mL) EEAD 0.18 0.04 0.11, 0.25 2.4x10-7 0.10 0.13 0.03 0.07, 0.20 6.6x10-5 0.18 
PAI-1 (U/mL) IEAD 0.18 0.05 0.09, 0.27 1.4x10-4 0.78 0.16 0.04 0.07, 0.25 2.6x10-4 0.79 
Fibrinogen* 
(g/L) 
EEAD 0.01 0.002 0.002, 0.009 0.002 0.004 0.004 0.002 9.5E-04, 0.007 0.01 0.03 
aPTT (s) EEAD -0.02 0.01 -0.04, -0.007 0.003 0.08 -0.02 0.01 -0.03, -0.006 0.005 0.12 
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Table 2. Summary of associations with P < 0.05.  
Table 2 gives an overall summary of associations with those Bonferroni significant in either 
the basic or full model marked. Blank cells indicate outcomes which did not achieve 
Bonferroni significance in either the basic or full model. Associations which were Bonferroni 
significant in the basic model but only nominally (P < 0.05) significant in the full model are 
marked with a single “+” or “-“. A blank cell indicates that the observed association had P > 
0.05. Effect estimates and p-values for all associations are given in Supplemental Tables 3 
and 4. AA = African ancestry population; aPTT = activated partial thromboplastin time; EA = 
European ancestry; EEAD = extrinsic epigenetic age acceleration difference; FVII = Factor 
VII; IEAD = intrinsic epigenetic age acceleration difference; PAI-1 = plasminogen activator 
inhibitor-1; RE = combined ancestry random effects model; vWF = von Willebrand Factor 
++ (--) = bonferonni significant positive (negative) association; + (-) = nominal (P < 0.05) 
significant positive (negative) association; * = combined race random effects meta-analysis  
Basic  Full
EEAD IEAD EEAD IEAD 
Fibrinogen* ++ +
PAI-1 ++ ++ ++ ++ 
D-dimer 
FVII 
vWF 
aPTT -- - 
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Table 3. Results from replication of fibrinogen and PAI-1 in FHS Generation 3 cohort. All 
aging measures were assessed in years while fibrinogen was measured in g/L and PAI-1 in 
U/mL. Replicated associations are given in bold. Basic model adjusted for age, age2, and sex. 
Full model adjusted for age, age2, sex, body mass index, smoking, and physical activity 
(where available). Additional linear and quadratic time difference terms were included in both 
models to represent the time between sample collection for the hemostatic factor assessment 
and assessment of DNA methylation. Effect estimates (Beta) are given per one year higher 
epigenetic age as compared to chronological age. AAD = age acceleration difference; Beta = 
effect estimate; EEAD = extrinsic epigenetic age acceleration difference; IEAD = intrinsic 
epigenetic age acceleration difference; LCI = lower 95% confidence interval; PAI-1 = 
plasminogen activator inhibitor-1; SE = standard error; UCI = upper 95% confidence interval 
Aging 
measure  
Hemostatic 
Factor 
Model Beta SE LCI UCI P 
EEAD Fibrinogen  Basic 6.4x10-3 3.4x10-3 -3.0x10-4 1.3x10-2 0.06 
IEAD Fibrinogen Basic 4.0x10-3 4.5x10-3 -4.7x10-3 1.3x10-2 0.37 
EEAD Fibrinogen Full -8.6x10-5 3.2x10-3 -6.4x10-3 6.2x10-3 0.98 
IEAD Fibrinogen Full -8.6x10-5 4.2x10-3 -8.3x10-3 8.1x10-3 0.98 
EEAD PAI-1 Basic 0.17 0.05 0.07 0.28 0.001 
IEAD PAI-1 Basic 0.16 0.07 0.03 0.29 0.01 
EEAD PAI-1 Full 0.05 0.05 -0.04 0.14 0.27 
IEAD PAI-1 Full 0.09 0.06 -0.03 0.20 0.16 
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Table 4. Association between epigenetic aging and gene expression. We examined the 
association between epigenetic age acceleration and gene expression using both cross-
sectional (4a, 4c) and prospective (4b) models in both peripheral blood (4a, 4b) and aorta 
intima-media samples (4c). Participating cohort abbreviated names are given in parentheses in 
the sub-table headings. In table 4a we give estimates from the meta-analysis of the cross-
sectional associations between epigenetic age acceleration and log2-transformed gene 
expression for KORA and RS. Both cohorts used different version of the same gene 
expression microarray which contained identical gene expression probe designs allowing for 
direct comparisons. For the prospective associations (4b), accelerated epigenetic aging was 
estimated in baseline (KORA S4) samples and gene expression measured in samples collected 
during follow-up 4-5 years later (KORA F4). Only associations with P < 0.05 in the full (age, 
age2, sex, body mass index, smoking, and physical activity) adjusted model are shown. Effect 
estimates (Beta) are given per one year higher epigenetic age as compared to chronological 
age. AAD = age acceleration difference; EEAD = extrinsic age acceleration difference; IEAD 
= intrinsic epigenetic age acceleration difference; P(Q) = P-value for heterogeneity; SE = 
standard error 
a. Cross-sectional meta-analysis (KORA F4 + RS)
Gene Aging 
Measure 
Estimate SE P Adjustment P(Q) 
FGA EEAD 0.002 0.001 0.05 Full 0.10 
SERPINE1 IEAD -0.002 0.001 0.04 Full 0.57 
b. Prospective associations (KORA S4)
Gene Aging 
Measure 
Estimate SE P Adjustment 
FGG IEAD 0.004 0.002 0.04 Full 
c. Aorta intima-media (ASAP)
Gene Aging 
Measure 
Estimate SE P Adjustment 
FGG AAD 0.009 0.004 0.046 Full
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Figure 1. Association between epigenetic aging and PAI-1. Sample sizes are given in 
parentheses next to the abbreviated cohort names. 
Effect estimates (Estimate) represent the association per one year higher epigenetic age as 
compared to chronological age as observed in the full model. AAD = epigenetic age 
acceleration difference; EEAD = extrinsic epigenetic age acceleration difference; IEAD = 
intrinsic epigenetic age acceleration difference; FE = fixed effects. 
Figure 2. Association between epigenetic aging and fibrinogen. Sample sizes are given in 
parentheses next to the abbreviated cohort names.  
Effect estimates (Estimate) represent the association per one year higher epigenetic age as 
compared to chronological age as observed in the full model. AAD = epigenetic age 
acceleration difference; EEAD = extrinsic epigenetic age acceleration difference; IEAD = 
intrinsic epigenetic age acceleration difference; FE = fixed effects; RE = random effects. 
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